Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
Titel:
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
Auteur:
Greco, F. Anthony Bonomi, Philip Crawford, Jeffrey Kelly, Karen Oh, Yun Halpern, Wendy Lo, Larry Gallant, Gilles Klein, Jerry